KR20080071095A - N,n―디메틸 이미도디카르본이미딕 디아미드의 초산염,그의 제조방법 및 그를 포함하는 약제학적 조성물 - Google Patents
N,n―디메틸 이미도디카르본이미딕 디아미드의 초산염,그의 제조방법 및 그를 포함하는 약제학적 조성물 Download PDFInfo
- Publication number
- KR20080071095A KR20080071095A KR1020080008991A KR20080008991A KR20080071095A KR 20080071095 A KR20080071095 A KR 20080071095A KR 1020080008991 A KR1020080008991 A KR 1020080008991A KR 20080008991 A KR20080008991 A KR 20080008991A KR 20080071095 A KR20080071095 A KR 20080071095A
- Authority
- KR
- South Korea
- Prior art keywords
- metformin
- formula
- acetate
- hydrochloride
- acetic acid
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (16)
- 제 1항에 있어서, 무수물, 반수화물 또는 일수화물 상태인 것을 특징으로 하는 화학식 1의 메트포르민 초산염.
- 제 1항에 있어서, 1가염인 것을 특징으로 하는 화학식 1의 메트포르민 초산염.
- 제 1항에 있어서, 당뇨병을 치료 및 예방하기 위한 화학식 1의 메트포르민 초산염.
- 제 5항 또는 제 6항에 있어서, 무기염류가 수산화나트륨 또는 수산화칼륨인 것을 특징으로 하는 화학식 1의 메트포르민 초산염의 제조방법.
- 제 5항 또는 제 6항에 있어서, 1 몰의 메트포르민 염산염과 반응하는 무기염류의 비율이 1 내지 2 몰비인 것을 특징으로 하는 화학식 1의 메트포르민 초산염의 제조방법.
- 제 5항에 있어서, 1몰의 메트포르민 유리염기와 반응하는 초산의 비율이 1 내지 2몰비인 것을 특징으로 하는 화학식 1의 메트포르민 초산염의 제조방법.
- 제 10항에 있어서, 유기알칼리가 탄산수소나트륨, 탄산칼륨, 초산나트륨 또는 초산나트륨 3수화물인 것을 특징으로 하는 화학식 1의 메트포르민 초산염의 제조방법.
- 제 10항에 있어서, 1 몰의 메트포르민 염산염과 반응하는 유기알칼리의 비율이 1 내지 2 몰비인 것을 특징으로 하는 메트포르민 초산염의 제조방법.
- 제 5항, 제 6항 및 제 10항 중 어느 한 항에 있어서, 상기반응이 -10 내지 50℃ 온도범위에서 수행되는 것을 특징으로 하는 제조방법.
- 제 5항 또는 제 6항에 있어서, 상기 유기용매가 물 또는 메탄올, 에탄올, 이 소프로판올, 아세톤 및 아세토니트릴로 구성된 군으로부터 선택되는 것을 특징으로 하는 제조방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070008835 | 2007-01-29 | ||
KR20070008835 | 2007-01-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080071095A true KR20080071095A (ko) | 2008-08-01 |
KR100926417B1 KR100926417B1 (ko) | 2009-11-12 |
Family
ID=39674247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080008991A KR100926417B1 (ko) | 2007-01-29 | 2008-01-29 | N,n―디메틸 이미도디카르본이미딕 디아미드의 초산염,그의 제조방법 및 그를 포함하는 약제학적 조성물 |
Country Status (6)
Country | Link |
---|---|
US (2) | US8058312B2 (ko) |
EP (1) | EP2109447B1 (ko) |
JP (1) | JP4592818B2 (ko) |
KR (1) | KR100926417B1 (ko) |
CN (2) | CN105152983A (ko) |
WO (1) | WO2008093984A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011049400A2 (ko) * | 2009-10-23 | 2011-04-28 | 한올바이오파마주식회사 | N,n-디메틸 이미도디카르본이미딕 디아미드의 산 부가염을 포함하는 항암용 약제학적 조성물 |
CN102093261A (zh) * | 2009-12-14 | 2011-06-15 | 中国药科大学 | 水杨酸二甲双胍盐、其制备方法及医药用途 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010146604A2 (en) | 2009-06-18 | 2010-12-23 | Exemed Pharmaceuticals | Processes for preparing metformin hydrochloride |
EP2522654A2 (en) * | 2010-01-06 | 2012-11-14 | HanAll Biopharma Co., Ltd. | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient |
WO2012090225A2 (en) * | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
WO2014011926A1 (en) * | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
CA2823397C (en) | 2011-01-07 | 2020-03-10 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
US20120178813A1 (en) * | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
CN102266325B (zh) * | 2011-07-28 | 2012-09-26 | 海南锦瑞制药股份有限公司 | 一种二甲双胍晶体及其与沙格列汀的药用组合物与制备方法 |
KR20190120430A (ko) | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
AU2013207329B2 (en) | 2012-01-06 | 2017-10-26 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
CA2913736A1 (en) | 2012-06-11 | 2013-12-19 | The Regents Of The University Of California | Compounds and methods of treating cancer |
CN102749348B (zh) * | 2012-06-18 | 2014-06-11 | 河南省科高植物天然产物开发工程技术有限公司 | 一种鉴别药用植物中活性成分组的方法 |
US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
CN103048347B (zh) * | 2012-08-15 | 2014-06-11 | 河南省科高植物天然产物开发工程技术有限公司 | 一种鉴别苦皮藤根皮药材的方法 |
WO2015171516A1 (en) | 2014-05-05 | 2015-11-12 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
KR20170023061A (ko) | 2014-06-18 | 2017-03-02 | 테티스 파마수티컬스 엘엘씨 | 활성제의 미네랄 아미노산 복합체 |
US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
AR108671A1 (es) * | 2016-06-03 | 2018-09-12 | Enlibrium Inc | Análogos de diamida imidodicarbonimidica |
CA3026264A1 (en) | 2016-06-03 | 2017-12-07 | Thetis Pharmaceuticals Llc | Compositions and methods relating to salts of specialized pro-resolving mediators |
US11510886B2 (en) | 2016-09-30 | 2022-11-29 | Laboratorios Silanes, S.A. De C.V. | Metformin amino acid compounds and methods of using the same |
WO2018060959A1 (en) | 2016-09-30 | 2018-04-05 | Laboratorios Silanes S.A. De C.V. | Metformin glycinate, pharmaceutical compositions comprising the same, and methods of using the same |
KR101992821B1 (ko) * | 2017-11-07 | 2019-06-25 | 전북대학교 산학협력단 | 골질환 예방 또는 치료용 약학 조성물 |
EP3801496A4 (en) * | 2018-06-05 | 2022-07-06 | Flagship Pioneering Innovations V, Inc. | ACTIVE AGENTS AND METHODS OF USE THEREOF FOR TREATING METABOLIC DISORDERS AND NAFLD |
CN115073331A (zh) * | 2021-03-15 | 2022-09-20 | 中国医学科学院药物研究所 | 二甲双胍肉桂酸盐一水合物及制备方法和其组合物与用途 |
CN113105367B (zh) * | 2021-03-30 | 2022-08-02 | 广州大学 | 一类二甲双胍盐及其制备方法和应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
FR2220256A1 (en) * | 1973-03-09 | 1974-10-04 | Nouvel Lucien | 1,1'-Dialkyl-biguanide theophyllin-7-acetates - with hypocholesterolaemic and hypolipamic activity |
FR2243684B1 (ko) | 1973-09-19 | 1977-01-28 | Semb | |
US4080472A (en) | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
CH602612A5 (ko) * | 1974-10-11 | 1978-07-31 | Hoffmann La Roche | |
FR2585572B3 (fr) * | 1985-07-31 | 1987-12-31 | Hugelin Andre | Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse |
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
FR2611500B1 (fr) * | 1987-03-06 | 1990-05-04 | Lipha | Emploi de derives du biguanide dans la preparation de medicaments |
DE69831335T3 (de) | 1997-06-06 | 2015-01-15 | Depomed, Inc. | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
WO1999029314A1 (en) * | 1997-12-08 | 1999-06-17 | Bristol-Myers Squibb Company | Novel salts of metformin and method |
CA2320900C (en) | 1998-03-19 | 2009-10-27 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
FR2809310B1 (fr) * | 2000-05-26 | 2004-02-13 | Centre Nat Rech Scient | Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant |
FR2812547B1 (fr) * | 2000-08-04 | 2002-10-31 | Lipha | Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete |
WO2003074039A1 (fr) | 2001-09-27 | 2003-09-12 | Mitsukan Group Corporation | Compositions permettant de prevenir l'hypertension |
US20050256195A1 (en) | 2000-12-26 | 2005-11-17 | Kenji Tayama | Composition for preventing hypertension |
ITFI20010054A1 (it) * | 2001-03-29 | 2002-09-29 | Menarini Farma Ind | Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii |
IN192180B (ko) | 2001-09-28 | 2004-03-06 | Ranbaxy Lab | |
EP1510208A1 (en) * | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
EP1591114A1 (en) * | 2004-03-12 | 2005-11-02 | Fournier Laboratories Ireland Limited | Use of metformin and orlistat for the treatment or prevention of obesity |
-
2008
- 2008-01-29 CN CN201510543331.4A patent/CN105152983A/zh active Pending
- 2008-01-29 KR KR1020080008991A patent/KR100926417B1/ko active IP Right Grant
- 2008-01-29 WO PCT/KR2008/000529 patent/WO2008093984A1/en active Application Filing
- 2008-01-29 US US12/524,695 patent/US8058312B2/en not_active Expired - Fee Related
- 2008-01-29 EP EP08712220.6A patent/EP2109447B1/en not_active Not-in-force
- 2008-01-29 JP JP2009547178A patent/JP4592818B2/ja not_active Expired - Fee Related
- 2008-01-29 CN CN200880010742A patent/CN101652131A/zh active Pending
-
2011
- 2011-09-23 US US13/241,731 patent/US8541474B2/en active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011049400A2 (ko) * | 2009-10-23 | 2011-04-28 | 한올바이오파마주식회사 | N,n-디메틸 이미도디카르본이미딕 디아미드의 산 부가염을 포함하는 항암용 약제학적 조성물 |
WO2011049400A3 (ko) * | 2009-10-23 | 2011-11-03 | 한올바이오파마주식회사 | N,n-디메틸 이미도디카르본이미딕 디아미드의 산 부가염을 포함하는 항암용 약제학적 조성물 |
CN102093261A (zh) * | 2009-12-14 | 2011-06-15 | 中国药科大学 | 水杨酸二甲双胍盐、其制备方法及医药用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2008093984A1 (en) | 2008-08-07 |
EP2109447B1 (en) | 2015-06-10 |
JP4592818B2 (ja) | 2010-12-08 |
US20100087544A1 (en) | 2010-04-08 |
US8058312B2 (en) | 2011-11-15 |
US20120010287A1 (en) | 2012-01-12 |
EP2109447A1 (en) | 2009-10-21 |
CN101652131A (zh) | 2010-02-17 |
US8541474B2 (en) | 2013-09-24 |
KR100926417B1 (ko) | 2009-11-12 |
EP2109447A4 (en) | 2011-08-17 |
JP2010516759A (ja) | 2010-05-20 |
CN105152983A (zh) | 2015-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100926417B1 (ko) | N,n―디메틸 이미도디카르본이미딕 디아미드의 초산염,그의 제조방법 및 그를 포함하는 약제학적 조성물 | |
KR101226669B1 (ko) | N,n-디메틸 이미도디카르본이미딕 디아미드의 디카르복실산염, 그의 제조 방법 및 그의 약제학적 조성물 | |
KR101190953B1 (ko) | 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 | |
US20120135952A1 (en) | Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same | |
KR101211227B1 (ko) | 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 | |
WO2012148252A2 (es) | Cocristales ionicos con base en metformina | |
KR101190957B1 (ko) | 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 | |
KR20200005320A (ko) | 무정형의 다파글리플로진 l-프롤린을 포함하는 약학적 제제 및 이의 제조방법 | |
US20170226119A1 (en) | Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof | |
KR20090005513A (ko) | 메트포르민 말론산염, 그의 제조 방법 및 그를 포함하는약제학적 조성물 | |
KR101324283B1 (ko) | 바이구아나이드 화합물의 신규 염, 그의 제조방법, 그를 포함하는 약제학적 조성물 | |
KR101104912B1 (ko) | N,n―디메틸 이미도디카르본이미딕 디아미드의 니코틴산염, 그의 제조방법 및 그를 포함하는 약제학적 조성물 | |
CN115073331A (zh) | 二甲双胍肉桂酸盐一水合物及制备方法和其组合物与用途 | |
NO854518L (no) | Nye fenoksypropanolaminsalter og farmasoeytiske preparater derav. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121102 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20131104 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20141104 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20151105 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20161103 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20171106 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20191105 Year of fee payment: 11 |